ASH 2012 home

Article

Cancer Network presents exclusive coverage from the American Society of Hematology (ASH) annual meeting. We'll bring you onsite reports as we cover the latest research, trials, scientific advances, and controversies that are changing the way hematologic malignancies are managed and treated.Check back here daily during the meeting and watch your inbox for our exciting reports from the ASH 2012 meeting.

Cancer Network presents exclusive coverage from the American Society of Hematology (ASH) annual meeting. We'll bring you onsite reports as we cover the latest research, trials, scientific advances, and controversies that are changing the way hematologic malignancies are managed and treated.

Check back here daily during the meeting and watch your inbox for our exciting reports from the ASH 2012 meeting.

Recent Videos
The poly-ICLC trial seeks to develop a delivery mechanism to prostate cancer through different biomarkers.
Related Content
The approval marks Foundation Medicine’s first companion diagnostic indication to exclusively support pediatric patients with brain tumors.

FDA Approves FoundationOne CDx Diagnostic for Tovorafenib in Brain Tumors

Roman Fabbricatore
January 20th 2025
Article

The approval marks Foundation Medicine’s first companion diagnostic indication to exclusively support pediatric patients with brain tumors.

Michael P. Bogenschutz, MD, discusses the efficacy, safety, implementation, and future research of psilocybin for cancer-related psychological events.

Psilocybin May Help Address Cancer-Related Psychological Concerns

Michael P. Bogenschutz, MD
January 20th 2025
Podcast

Michael P. Bogenschutz, MD, discusses the efficacy, safety, implementation, and future research of psilocybin for cancer-related psychological events.

Micheal P. Bogenschutz, MD, discussed addressing unmet needs, implementation, and adverse effects related to psilocybin-assisted psychotherapy in cancer.

Integrating Psilocybin-Assisted Psychotherapy in Comprehensive Cancer Care

Michael P. Bogenschutz, MD
January 20th 2025
Article

Micheal P. Bogenschutz, MD, discussed addressing unmet needs, implementation, and adverse effects related to psilocybin-assisted psychotherapy in cancer.

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

FDA Grants Breakthrough Device Designation to Biosignature Test in DCIS

FDA Grants Breakthrough Device Designation to Biosignature Test in DCIS

Tim Cortese
January 18th 2025
Article

The DCISionRT test has shown to be a significant factor in a clinician’s recommendation on whether a patient with DCIS should receive radiotherapy.

UGN-102 May Be Nonsurgical Alternative to TURBT in Low-grade Bladder Cancer

UGN-102 May Be Nonsurgical Alternative to TURBT in Low-grade Bladder Cancer

Tim Cortese
January 18th 2025
Article

UGN-102 elicited complete responses in 79.6% of patients with non–muscle-invasive bladder cancer at 3 months in the ENVISION trial.